NZ628421A - Treatment of cancer with tor kinase inhibitors - Google Patents

Treatment of cancer with tor kinase inhibitors

Info

Publication number
NZ628421A
NZ628421A NZ628421A NZ62842113A NZ628421A NZ 628421 A NZ628421 A NZ 628421A NZ 628421 A NZ628421 A NZ 628421A NZ 62842113 A NZ62842113 A NZ 62842113A NZ 628421 A NZ628421 A NZ 628421A
Authority
NZ
New Zealand
Prior art keywords
tor kinase
cancer
treatment
kinase inhibitors
ewings sarcoma
Prior art date
Application number
NZ628421A
Other languages
English (en)
Inventor
Shuichan Xu
Kristen Mae Hege
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of NZ628421A publication Critical patent/NZ628421A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ628421A 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors NZ628421A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611370P 2012-03-15 2012-03-15
US201261715329P 2012-10-18 2012-10-18
PCT/US2013/031202 WO2013138556A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (1)

Publication Number Publication Date
NZ628421A true NZ628421A (en) 2016-04-29

Family

ID=47998542

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628421A NZ628421A (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Country Status (20)

Country Link
US (1) US20130245029A1 (enExample)
EP (1) EP2825168B1 (enExample)
JP (2) JP2015516375A (enExample)
KR (3) KR20200034818A (enExample)
CN (2) CN107137402A (enExample)
AU (1) AU2013203156C1 (enExample)
BR (1) BR112014022697A2 (enExample)
CA (1) CA2867349A1 (enExample)
EA (1) EA028434B1 (enExample)
ES (1) ES2677908T3 (enExample)
IL (2) IL234640B (enExample)
MX (1) MX360877B (enExample)
MY (1) MY182650A (enExample)
NI (1) NI201400109A (enExample)
NZ (1) NZ628421A (enExample)
PH (2) PH12014502048B1 (enExample)
SG (1) SG11201405706TA (enExample)
TW (2) TWI600428B (enExample)
WO (1) WO2013138556A1 (enExample)
ZA (1) ZA201406709B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
ES2944478T3 (es) 2013-04-17 2023-06-21 Signal Pharm Llc 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
KR102242505B1 (ko) 2013-04-17 2021-04-20 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
HUE054548T2 (hu) * 2016-12-20 2021-09-28 Astrazeneca Ab Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
JP7466450B2 (ja) 2018-03-01 2024-04-12 エシロール・アンテルナシオナル レンズ要素
CN113493471B (zh) * 2020-04-03 2024-06-11 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383370T3 (es) 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
EP2457913B1 (en) * 2006-10-19 2017-04-19 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
JP2013508456A (ja) 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
CA2867349A1 (en) 2013-09-19
TWI664968B (zh) 2019-07-11
KR102057358B1 (ko) 2019-12-18
BR112014022697A2 (pt) 2020-06-30
EA028434B1 (ru) 2017-11-30
WO2013138556A1 (en) 2013-09-19
EA201491694A1 (ru) 2015-06-30
KR20140138929A (ko) 2014-12-04
HK1201755A1 (en) 2015-09-11
TW201343167A (zh) 2013-11-01
AU2013203156C1 (en) 2016-02-18
IL234640B (en) 2020-05-31
TW201733586A (zh) 2017-10-01
IL234640A0 (en) 2014-11-30
PH12014502048A1 (en) 2014-12-10
ES2677908T3 (es) 2018-08-07
JP2015516375A (ja) 2015-06-11
TWI600428B (zh) 2017-10-01
JP6470821B2 (ja) 2019-02-13
JP2018065820A (ja) 2018-04-26
CN107137402A (zh) 2017-09-08
KR20200034818A (ko) 2020-03-31
AU2013203156A1 (en) 2013-10-03
AU2013203156B2 (en) 2015-12-10
MY182650A (en) 2021-01-27
MX2014011117A (es) 2015-04-08
IL274318A (en) 2020-06-30
EP2825168B1 (en) 2018-05-09
SG11201405706TA (en) 2014-10-30
EP2825168A1 (en) 2015-01-21
ZA201406709B (en) 2016-07-27
US20130245029A1 (en) 2013-09-19
MX360877B (es) 2018-11-21
CN104302295A (zh) 2015-01-21
NI201400109A (es) 2015-01-15
CN104302295B (zh) 2017-06-20
KR20190058673A (ko) 2019-05-29
PH12018502234A1 (en) 2019-08-14
PH12014502048B1 (en) 2020-10-28
PH12018502234B1 (en) 2021-07-23

Similar Documents

Publication Publication Date Title
NZ628421A (en) Treatment of cancer with tor kinase inhibitors
NZ628420A (en) Treatment of cancer with tor kinase inhibitors
NZ628407A (en) Treatment of cancer with tor kinase inhibitors
NZ628416A (en) Treatment of cancer with tor kinase inhibitors
IL281180A (en) 1-Ethyl-7-(2-methyl-6-(4H-4,2,1-triazol-3-yl)pyridin-3-yl)-4,3-dihydropyrazino[3,2-b]pyrazine-2 (1H)-one for cancer treatment
MX2013011518A (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de desordenes del sistema nervioso y cancer.
PL3808749T3 (pl) Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
EA025281B9 (ru) СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
MX357502B (es) Derivados de pirrolotriazinona.
NZ629230A (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
IL241950B (en) Compound 1-ethyl-7-(2-methyl-6-(1h-4,2,1-triazol-3-yl)pyridin-3-yl)-4,3-dihydropyrazino[2,3-b]pyrazine- 2(1h)-ven for the treatment of glioblastoma multiforme
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
MX2014011326A (es) Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.
NZ714742A (en) Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2014153464A3 (en) 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
NZ629459A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
NZ717887A (en) Treatment of cancer with tor kinase inhibitors
TH165140A (th) การรักษามะเร็งด้วยตัวยับยั้ง tor ไคเนส
NZ781485A (en) Benzolactam compounds as protein kinase inhibitors
AP3582A (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190219

LAPS Patent lapsed